Trial · NCT02513550
Adverse events1,608
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,608
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neutropenia | Blood and lymphatic system disorders | Ixekizumab 80 mg Q4W - Treatment Period | 2 | 310 | 2 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q4W/Q2W - Treatment Period | 0 | 306 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q2W - Treatment Period | 1 | 609 | 2 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q4W - Post-Treatment Period | 0 | 285 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period | 0 | 283 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q2W - Post-Treatment Period | 1 | 559 | 1 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q4W - Treatment Period ME2 Cohort | 0 | 9 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q4W/Q2W - Treatment Period ME2 Cohort | 0 | 5 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q2W - Treatment Period ME2 Cohort | 1 | 16 | 1 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q4W - Post-Treatment Period ME2 Cohort | 0 | 9 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period ME2 Cohort | 0 | 4 | 0 |
| other | Neutropenia | Blood and lymphatic system disorders | 80 mg Ixekizumab Q2W - Post-Treatment Period ME2 Cohort | 0 | 15 | 0 |
| other | Retinal vein occlusion | Eye disorders | Ixekizumab 80 mg Q4W - Treatment Period | 0 | 310 | 0 |
| other | Retinal vein occlusion | Eye disorders | 80 mg Ixekizumab Q4W/Q2W - Treatment Period | 0 | 306 | 0 |
| other | Retinal vein occlusion | Eye disorders | 80 mg Ixekizumab Q2W - Treatment Period | 0 | 609 | 0 |
| other | Retinal vein occlusion | Eye disorders | 80 mg Ixekizumab Q4W - Post-Treatment Period | 0 | 285 | 0 |
| other | Retinal vein occlusion | Eye disorders | 80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period | 0 | 283 | 0 |
| other | Retinal vein occlusion | Eye disorders | 80 mg Ixekizumab Q2W - Post-Treatment Period | 0 | 559 | 0 |
| other | Retinal vein occlusion | Eye disorders | 80 mg Ixekizumab Q4W - Treatment Period ME2 Cohort | 0 | 9 | 0 |
| other | Retinal vein occlusion | Eye disorders | 80 mg Ixekizumab Q4W/Q2W - Treatment Period ME2 Cohort | 0 | 5 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02513550/events